Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Philip Sabato"'
Autor:
Marita Prohn, Anders Viberg, Da Zhang, Kevin Dykstra, Casey Davis, Sreeraj Macha, Philip Sabato, Dinesh deAlwis, Marian Iwamoto, Craig Fancourt, Carolyn R. Cho
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 3, Pp 255-267 (2021)
Abstract Letermovir is indicated for prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Two‐stage population pharmacokinetic (PK) modeling of letermovir was conducted to support
Externí odkaz:
https://doaj.org/article/6266540773034cbfab636e1891cbf5e5
Autor:
Randi Y. Leavitt, Anders Viberg, Carolyn R. Cho, Craig Fancourt, Julie A. Stone, Sreeraj Macha, Yoshihiko Murata, Marita Prohn, Cyrus Badshah, Philip Sabato, Kevin Dykstra, Casey Davis
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:485-495
The cytomegalovirus (CMV) viral terminase inhibitor letermovir is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplantation recipients. In a phase III trial (NCT02137772), leter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe4008fba73a1a300982aed78a27fdc
https://doi.org/10.1002/cpt.2456
https://doi.org/10.1002/cpt.2456
Autor:
Philip Sabato, Margaret Z Chou, Pamela Sears, Carisa De Anda, Oleksandr Fofanov, Camilla Tøndel, Antonio Arrieta, Dan Li, Claudia M Espinosa, Jason Y Kim, Jocelyn Y. Ang, John S. Bradley
Publikováno v:
Pediatric Infectious Disease Journal. 40:317-323
BACKGROUND Infections with Gram-positive bacteria, including acute bacterial skin and skin structure infections (ABSSSIs), are common in children. We describe a single-dose pharmacokinetics and safety study of tedizolid phosphate, a new oxazolidinone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042357cc48bf757b8727aa845604a663
https://doi.org/10.1097/inf.0000000000003030
https://doi.org/10.1097/inf.0000000000003030
Autor:
Jenny Huimin Zheng, David Wesche, Philip Sabato, Radojka M. Savic, Abhay Joshi, Melanie R. Nicol, Jack Cook, Matthew L. Rizk
Publikováno v:
Clinical Pharmacology and Therapeutics
Clinical pharmacology and therapeutics, vol 108, iss 6
Clinical Pharmacology & Therapeutics
Clinical pharmacology and therapeutics, vol 108, iss 6
Clinical Pharmacology & Therapeutics
Chloroquine and hydroxychloroquine are quinoline derivatives used to treat malaria. To date, these medications are not approved for the treatment of viral infections and there are no well‐controlled, prospective, randomized clinical studies or evid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e700c49a20fb9c56ff9a1b075555e356
https://doi.org/10.1002/cpt.1993
https://doi.org/10.1002/cpt.1993
Autor:
Hwa-Ping Feng, Vincent Duval, Matthew L. Rizk, Dan Li, Carisa De Anda, Margaret Z Chou, Philip Sabato, Aziz Ouerdani, Natalya Broyde, Benjamin Guiastrennec, Pamela Sears, Catherine Hardalo
Publikováno v:
Antimicrobial Agents and Chemotherapy
Tedizolid phosphate is an oxazolidinone antibacterial agent approved for the treatment of Gram-positive acute bacterial skin and skin structure infections (ABSSSIs) in patients aged ≥12 years. To support the use of tedizolid phosphate in adolescent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd357881778f3992e613ca2dee02e49
http://europepmc.org/articles/PMC8597753
http://europepmc.org/articles/PMC8597753
Autor:
Carolyn R. Cho, Sreeraj Macha, Anders Viberg, Philip Sabato, Marian Iwamoto, Casey Davis, Da Zhang, Dinesh P. de Alwis, Kevin Dykstra, Craig Fancourt, Marita Prohn
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 3, Pp 255-267 (2021)
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 3, Pp 255-267 (2021)
Letermovir is indicated for prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Two‐stage population pharmacokinetic (PK) modeling of letermovir was conducted to support dose rati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3adaaff6709665bea16013469ba79ad8
https://pubmed.ncbi.nlm.nih.gov/33440077
https://pubmed.ncbi.nlm.nih.gov/33440077